Accueil   Diary - News   All news Valneva Announces Signing of a New EB66® Commercial License with Bavarian Nordic

Valneva Announces Signing of a New EB66® Commercial License with Bavarian Nordic

Lyon (France), April 18, 2017 – Valneva SE (“Valneva” or “the Company”), a fully integrated, commercial stage biotech company focused on developing innovative lifesaving vaccines, today announced that it has entered into a commercial agreement with Danish biotech company Bavarian Nordic (OMX: BAVA, OTC:BVNRY), for the production of poxvirus-based vaccines using Valneva´s EB66® cell-line technology.

 

 

The agreement grants Bavarian Nordic the rights to develop and commercialize multiple poxvirus-based vaccines on the EB66® cell-line.

 

Read the press release